Stock 002007 HUALAN BIOLOGICAL ENGINEERING INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hualan Biological Engineering Inc.

Equities

002007

CNE000001JN8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
19.47 CNY +0.05% Intraday chart for Hualan Biological Engineering Inc. +1.20% -12.02%
Apr. 25 Hualan Biological Engineering Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 Hualan Biological Engineering's Profit Rises 38%; Tops EPS, Revenue Estimates MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 49,318 77,061 53,162 41,285 40,471 35,606 - -
Enterprise Value (EV) 1 48,254 76,423 53,470 41,288 40,478 33,215 33,128 30,617
P/E ratio 38.3 x 48 x 41.1 x 38.4 x 27.3 x 19.8 x 17.5 x 15.1 x
Yield 1.14% 0.71% 0.69% 1.33% 1.36% 1.36% 1.97% 1.39%
Capitalization / Revenue 13.3 x 15.3 x 12 x 9.14 x 7.58 x 5.6 x 4.95 x 4.31 x
EV / Revenue 13 x 15.2 x 12.1 x 9.14 x 7.58 x 5.22 x 4.6 x 3.71 x
EV / EBITDA 27.2 x 32.7 x 28 x 24.1 x 17.1 x 12.9 x 11.4 x 8.97 x
EV / FCF 44.3 x 109 x 86 x 67.3 x 50.8 x 20.4 x 13.4 x 13.2 x
FCF Yield 2.26% 0.92% 1.16% 1.49% 1.97% 4.9% 7.47% 7.59%
Price to Book 7.54 x 10.1 x 6.38 x 3.97 x 3.56 x 2.83 x 2.45 x 2.25 x
Nbr of stocks (in thousands) 1,823,977 1,824,367 1,824,367 1,824,367 1,828,781 1,828,781 - -
Reference price 2 27.04 42.24 29.14 22.63 22.13 19.47 19.47 19.47
Announcement Date 2/28/20 3/10/21 3/29/22 3/29/23 3/29/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,700 5,023 4,436 4,517 5,342 6,362 7,199 8,253
EBITDA 1 1,776 2,337 1,913 1,712 2,372 2,566 2,916 3,414
EBIT 1 1,615 2,137 1,696 1,424 2,098 2,471 2,744 3,282
Operating Margin 43.65% 42.54% 38.24% 31.54% 39.28% 38.83% 38.12% 39.77%
Earnings before Tax (EBT) 1 1,610 2,134 1,688 1,428 2,078 2,508 2,773 3,312
Net income 1 1,283 1,604 1,299 1,076 1,482 1,798 2,030 2,357
Net margin 34.69% 31.94% 29.28% 23.83% 27.74% 28.26% 28.2% 28.56%
EPS 2 0.7063 0.8795 0.7094 0.5888 0.8121 0.9833 1.111 1.287
Free Cash Flow 1 1,090 704 622.1 613.7 796.5 1,627 2,476 2,324
FCF margin 29.46% 14.01% 14.02% 13.59% 14.91% 25.57% 34.4% 28.16%
FCF Conversion (EBITDA) 61.36% 30.12% 32.52% 35.85% 33.59% 63.4% 84.9% 68.06%
FCF Conversion (Net income) 84.92% 43.88% 47.89% 57.02% 53.76% 90.5% 121.97% 98.59%
Dividend per Share 2 0.3077 0.3000 0.2000 0.3000 0.3000 0.2650 0.3826 0.2700
Announcement Date 2/28/20 3/10/21 3/29/22 3/29/23 3/29/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,075 640.7 1,709 1,253 914.6 880.7 704.6 2,328 1,429 787.3 865.7 2,799 1,741 858.2
EBITDA - - - - - - - - - - - - - -
EBIT 1 306.8 277.2 512 456.8 178.5 452.4 246 868.1 531.8 331.1 373.9 1,156 787.7 311.9
Operating Margin 28.54% 43.27% 29.96% 36.46% 19.51% 51.38% 34.92% 37.29% 37.22% 42.06% 43.2% 41.29% 45.24% 36.34%
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - -
EPS 2 0.1300 0.1281 0.1900 0.1700 0.1000 0.1928 0.1000 0.3000 0.2200 0.1431 0.1400 0.4500 0.3100 0.1400
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 3/29/22 4/28/22 8/22/22 10/30/22 3/29/23 4/21/23 8/23/23 10/29/23 3/29/24 4/25/24 - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 308 2.18 6.94 - - -
Net Cash position 1 1,064 638 - - - 2,392 2,478 4,989
Leverage (Debt/EBITDA) - - 0.1612 x 0.001276 x 0.002925 x - - -
Free Cash Flow 1 1,090 704 622 614 797 1,627 2,476 2,324
ROE (net income / shareholders' equity) 19.9% 23% 16.5% 11.1% 13.7% 14.1% 13.6% 13.8%
ROA (Net income/ Total Assets) 18.2% 18.2% 12% 8.19% - 10.1% 10.1% 11.4%
Assets 1 7,038 8,812 10,788 13,139 - 17,800 20,099 20,769
Book Value Per Share 2 3.590 4.170 4.570 5.700 6.210 6.870 7.930 8.640
Cash Flow per Share 2 0.7500 0.7300 0.7800 0.5200 0.7400 0.9900 1.000 1.100
Capex 1 273 621 810 344 549 330 332 392
Capex / Sales 7.37% 12.37% 18.27% 7.61% 10.28% 5.18% 4.61% 4.75%
Announcement Date 2/28/20 3/10/21 3/29/22 3/29/23 3/29/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hualan Biological Engineering Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
19.47 CNY
Average target price
25.78 CNY
Spread / Average Target
+32.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
HUALAN BIOLOGICAL ENGINEERING INC. Stock Hualan Biological Engineering Inc.
-12.02% 4.92B
CSL LIMITED Stock CSL Limited
-3.35% 86.16B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.76% 40.17B
BIOGEN INC. Stock Biogen Inc.
-17.49% 31.47B
UCB Stock UCB
+54.44% 25.24B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-13.13% 15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.96B
INCYTE CORPORATION Stock Incyte Corporation
-15.45% 11.89B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.84B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 002007 Stock
  4. Financials Hualan Biological Engineering Inc.